Life Sciences Tools and Services
Company Overview of RainDance Technologies, Inc.
RainDance Technologies, Inc. develops, manufactures, and sells proprietary systems, consumables, and assays that enable ultra-sensitive detection and analysis of complex genetic diseases in tissue and liquid biopsies in life science and translational research settings. The company offers ThunderStorm system that generates one million unique droplet-based single molecule polymerase chain reaction reactions for approximately 20,000 targeted genetic loci, or specific regions of the genome; and provides sensitivity, accuracy, genomic coverage, and uniformity to commercial service laboratories. It also offers ThunderBolts system that provides predefined assays, or primers that target genetic regi...
749 Middlesex Turnpike
Billerica, MA 01821
Founded in 2004
Key Executives for RainDance Technologies, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2015.
RainDance Technologies, Inc. Key Developments
RainDance Technologies, Inc. and Blood Systems Research Institute Collaborate to Develop Ultra-Sensitive Assays to Detect and Quantify HIV Latency
Dec 7 15
RainDance Technologies, Inc. and Blood Systems Research Institute announced a research collaboration to develop blood-based assays and protocols for the precise measurement of the human immunodeficiency virus (HIV) latent reservoir using RainDance’s RainDrop Digital PCR and ThunderBolts Next-Generation Sequencing (NGS) Enrichment Systems. As part of this collaboration, BSRI will provide access to the RainDance products to key thought leaders at the new amfAR Institute for HIV Cure Research, an innovative collaborative enterprise focused on developing and validating new approaches that can ultimately lead to a functional cure for HIV. Built on RainDance’s unified picodroplet platform, the RainDrop and ThunderBolts Systems generate millions of individual droplet-based tests per sample, providing the dynamic range and quantitation essential for massively-parallel yet precise single molecule analysis. The collaboration between RainDance and BSRI aims to develop ultra-sensitive, highly precise and low cost NGS and digital PCR methods to detect, measure and monitor replication competent latent HIV with absolute quantitation from limited amounts of bio-available fluids.
RainDance Technologies, Inc. Appoints Kathy Ordonez as the Chairman of the Board of Directors
Sep 24 15
RainDance Technologies, Inc. announced the appointment of Kathy Ordoez as chairman of its board of directors. Ms. Ordoez brings more than 30 years of experience in the life sciences and diagnostics industries, and has served on the board of directors since 2014, and as the chair of the board’s science and innovation committee. As senior vice president at Quest Diagnostics, Kathy Ordoez was responsible for leading the company's businesses in diagnostic products, insurer services, clinical trials and healthcare information technology products and also led research and development. Ordoez was previously the chief executive officer at Celera and a founder of Celera Diagnostics.
Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. Partner to Co-Develop and Commercialize Novel Solution For de novo Whole Genome Assembly
May 5 15
Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. announced their entry into a co-development and co-marketing agreement to commercialize novel solutions for de novo whole genome assembly. These solutions will combine the power of RainDance's proprietary digital droplet technology and single-molecule barcoding capabilities with Pacific Biosciences' proprietary long-range DNA amplification technology to provide sample preparation upstream of PacBio's long-read sequencing system. This combination could provide a method to generate millions of long, single-molecule barcoded DNA fragments, averaging 10-30 kilobases that originated from much longer (100 kilobase) fragments. Combining this fragmentation and labeling scheme with a sequence context-unbiased amplification method for long DNA fragments, PacBio sequencing could provide de novo, haplotype-phased assembly of complex genomes. This would be possible even in genomic regions containing complex repeats or PCR-challenged sequences that limit performance of synthetic long-read approaches based upon short-read sequencing technologies. Furthermore, this approach will be designed to work with low DNA input as little as 1 ng to address scarce or difficult-to-procure samples.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|